3-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)pyrrolidin-3-ol | 1136651-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 3-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)pyrrolidin-3-ol
• CAS: 1136651-03-0
• 化学式: C₁₉H₁₉ClN₂O
• 分子量: 326.826
• InChiKey: PVPFHWKNLSESPB-UHFFFAOYSA-N

物化性质

• 熔点：
  56.9-57.2 °C
• 沸点：
  531.1±50.0 °C(predicted)
• 密度：
  1.350±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  39.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吲哚 、 聚合甲醛 、 3-(4-chlorophenyl)-3-hydroxypyrrolidine 在 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以49%的产率得到3-(4-chlorophenyl)-1-(1H-indol-3-ylmethyl)pyrrolidin-3-ol
  参考文献：
  名称：

  Synthesis and evaluation of ligands for D2-like receptors: The role of common pharmacophoric groups

  摘要：

  Arylcycloalkylamines, such as phenyl piperidines and piperazines and their arylalkyl substituents, constitute pharmacophoric groups exemplified in several antipsychotic agents. A review of previous reports indicates that arylalkyl substituents can improve the potency and selectivity of the binding affinity at D-2-like receptors. In this paper, we explored the contributions of two key pharmacophoric groups, that is, 40-fluorobutyrophenones and 3-methyl-7-azaindoles, to the potency and selectivity of synthesized agents at D-2-like receptors. Preliminary observation of binding affinities indicates that there is little predictability of specific effects of the arylalkyl moieties but the composite structure is responsible for selectivity and potency at these receptors. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.12.054

文献信息

• TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
  申请人：MEDICONNS (SHANGHAI) BIOPHARMACEUTICAL CO., LTD

  公开号：US20210024498A1

  公开（公告）日：2021-01-28

  The present invention discloses a tetrahydropyrrole compound, a preparation method therefor, a pharmaceutical composition containing the same, and a use thereof. The tetrahydropyrrole compound of the present invention is represented by general formula (I). The tetrahydropyrrole compound of the present invention has better inhibitory effects on the positive symptoms of schizophrenia, and the potency thereof is equivalent to or slightly stronger than that of the positive drug olanzapine. In addition, the compound of the present invention has dual inhibitory effects on D2 receptors and DAT receptors, and is effective for treating schizophrenia and improving negative symptoms and cognitive functions, while also reducing vertebral side effects and prolactin secretion.